GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2

A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Extension Study of Protocol 137OB-201 to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Lead sponsor

AstraZeneca

Asset

Pramlintide

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

—

Enrollment

210

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoints

•Examine the long-term effect of subcutaneously (SC) injected pramlintide•Examine the long-term safety and tolerability of SC injected pramlintide

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00189514

Org study ID137OB-201E

Timeline

Milestones

Study first posted2005-09-19estimated

Last update posted2015-06-11estimated

Study start2005-09 (month precision)

Primary completion2007-06actual (month precision)

Study completion2007-06actual (month precision)

Assets

Investigational agents

Pramlintide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Eligibility criteria

•Subject has completed Protocol 137OB-201.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Safety / tolerability / PK

Other (unclassified)

Weight & body composition

1 endpoint

Primary/protocol endpoint

Examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight in obese subjects.

Time frame:open ended

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

Examine the long-term safety and tolerability of SC injected pramlintide in obese subjects.

Time frame:open ended

descriptive

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Investigate the long-term effect of SC injected pramlintide in obese subjects on various anthropometric and pharmacodynamic parameters.

Time frame:open ended

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.
Diabetes care2008 Sep (month)PMID18753666doi:10.2337/dc08-0029via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.